Literature DB >> 26921820

Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.

Fleur M Aung1, Benjamin Lichtiger1, Gabriela Rondon2, C Cameron Yin3, Amin Alousi2, Sairah Ahmed2, Borje S Andersson2, Qaiser Bashir2, Stefan O Ciurea2, Chitra Hosing2, Roy Jones2, Partow Kebriaei2, Issa Khouri2, Yago Nieto2, Betul Oran2, Simrit Parmar2, Muzaffar Qazilbash2, Nina Shah2, Elizabeth J Shpall2, Richard E Champlin2, Uday Popat4.   

Abstract

In major ABO-mismatched allogeneic hematopoietic stem cell transplantation (HSCT) persistence of antidonor isohemagglutinins leads to pure red cell aplasia (PRCA). To investigate severe pancytopenia noted in a previous study of PRCA, we analyzed all major ABO-mismatched HSCT between January 2003 and December 2012. Of 83 PRCA patients, 13 (16%) had severe pancytopenia. Severe pancytopenia was defined as an absolute neutrophil count (ANC) < 1.5 K/μL or requiring granulocyte colony-stimulating factor, platelets < 50 K/μL or transfusion dependent, and PRCA with RBC transfusion dependence at post-transplant day 90. In 6 patients (46%) severe pancytopenia resolved after PRCA resolution. Two patients (15%) received a second transplant because of persistent pancytopenia/secondary graft failure, 1 (8%) died from secondary graft failure despite a stem cell boost, 1 (8%) did not recover his platelet counts despite RBC/ANC recovery, and 3 patients (23%) died from disease relapse. We found that severe pancytopenia is frequently associated with PRCA in 16% of major ABO-incompatible HSCT with a higher incidence in males and pancytopenia resolved with resolution of PRCA in 46% of patients.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hematopoietic stem cell transplant; Pancytopenia; Pure red cell aplasia

Mesh:

Substances:

Year:  2016        PMID: 26921820      PMCID: PMC7176024          DOI: 10.1016/j.bbmt.2016.02.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  22 in total

1.  Blood group A and B antigens are strongly expressed on platelets of some individuals.

Authors:  B R Curtis; J T Edwards; M J Hessner; J P Klein; R H Aster
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

Review 2.  Progress in haploidentical stem cell transplantation.

Authors:  Ulas D Bayraktar; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

3.  Impact of donor-recipient major ABO mismatch on allogeneic transplantation outcome according to stem cell source.

Authors:  Nicolas Blin; Richard Traineau; Stéphanie Houssin; Régis Peffault de Latour; Anna Petropoulou; Marie Robin; Jérôme Larghero; Patricia Ribaud; Gérard Socié
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-29       Impact factor: 5.742

Review 4.  ABO-histo blood group incompatibility in hematopoietic stem cell and solid organ transplantation.

Authors:  Georg Stussi; Jörg Halter; Urs Schanz; Jörg D Seebach
Journal:  Transfus Apher Sci       Date:  2006-08-28       Impact factor: 1.764

5.  Status of major red cell blood group antigens on neutrophils, lymphocytes and monocytes.

Authors:  R A Dunstan
Journal:  Br J Haematol       Date:  1986-02       Impact factor: 6.998

6.  The expression of ABH antigens during in vitro megakaryocyte maturation: origin of heterogeneity of antigen density.

Authors:  R A Dunstan
Journal:  Br J Haematol       Date:  1986-03       Impact factor: 6.998

7.  Evaluation of individual specificities of class I HLA on platelets by a newly developed monoclonal antibody.

Authors:  K J Kao; J C Scornik; C F McQueen
Journal:  Hum Immunol       Date:  1990-04       Impact factor: 2.850

8.  Impact of ABO incompatibility on allogeneic peripheral blood progenitor cell transplantation after reduced intensity conditioning.

Authors:  Carmen Canals; Eduardo Muñiz-Díaz; Clara Martínez; Rodrigo Martino; Imma Moreno; Adelaida Ramos; Marina Arilla; Neus Boto; Concepción Pastoret; Angel Remacha; Jorge Sierra; Pedro Madoz
Journal:  Transfusion       Date:  2004-11       Impact factor: 3.157

9.  Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect.

Authors:  M Mielcarek; W Leisenring; B Torok-Storb; R Storb
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

10.  Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation.

Authors:  Fleur M Aung; Benjamin Lichtiger; Roland Bassett; Ping Liu; Amin Alousi; Qaiser Bashier; Stefan O Ciurea; Marcos J de Lima; Chitra Hosing; Partow Kebriaei; Yago Nieto; Betul Oran; Simrit Parmar; Muzaffar Qazilbash; Nina Shah; Issa Khouri; Richard E Champlin; Uday Popat
Journal:  Br J Haematol       Date:  2013-01-18       Impact factor: 6.998

View more
  6 in total

1.  Use of anti-thymocyte globulin (ATG) for the treatment of pure red cell aplasia and immune-mediated cytopenias after allogeneic hematopoietic cell transplantation: a case series.

Authors:  Alexandra Gomez-Arteaga; Michael Scordo; Roni Tamari; Josel D Ruiz; Ann A Jakubowski; Esperanza B Papadopoulos; Sergio A Giralt; Miguel-Angel Perales; Hugo R Castro-Malaspina; Craig S Sauter; Parastoo B Dahi
Journal:  Bone Marrow Transplant       Date:  2020-05-18       Impact factor: 5.483

Review 2.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

3.  Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Thiti Asawapanumas; Chantiya Chanswangphuwana; Phandee Watanaboonyongcharoen; Ponlapat Rojnuckarin; Udomsak Bunworasate
Journal:  Leuk Res Rep       Date:  2022-04-13

4.  ABO incompatibility does not affect transfusion requirements or clinical outcomes of unrelated cord blood transplantation after myeloablative conditioning for haematological malignancies.

Authors:  Yang Chen; Xiaoju Wan; Yuan Cao; Huiru Wang; Dandan Han; Yuangyuang Zhang; Wen Yao; Kaidi Song; Qian Fan; Xiaoyu Zhu; Ziming Sun; Huilan Liu
Journal:  Blood Transfus       Date:  2021-07-02       Impact factor: 3.443

5.  Antigen-Specific Immunoadsorption With the Glycosorb® ABO Immunoadsorption System as a Novel Treatment Modality in Pure Red Cell Aplasia Following Major and Bidirectional ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Ammon Handisurya; Nina Worel; Werner Rabitsch; Marija Bojic; Sahra Pajenda; Roman Reindl-Schwaighofer; Wolfgang Winnicki; Andreas Vychytil; Hanna A Knaus; Rainer Oberbauer; Kurt Derfler; Philipp Wohlfarth
Journal:  Front Med (Lausanne)       Date:  2020-10-22

6.  ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes.

Authors:  Caterina Giovanna Valentini; Elisabetta Metafuni; Lorenzo Gallo; Sabrina Giammarco; Nicoletta Orlando; Maria Bianchi; Simona Sica; Andrea Bacigalupo; Patrizia Chiusolo; Luciana Teofili
Journal:  Transplant Direct       Date:  2021-07-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.